RUCONEST® (recombinant human C1 esterase inhibitor)
RUCONEST is an investigational product that is a recombinant human C1 esterase inhibitor protein for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). A Biologics License Application for RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema is under review by the U.S. Food and Drug Administration with a response expected in April 2014. RUCONEST has been granted orphan drug designation in the U.S. for the treatment of acute attacks of HAE, a rare, genetic disorder caused by a deficiency in functional C1 inhibitor, a plasma protein, resulting in unpredictable episodes of intense swelling of the extremities, face, trunk, genitals, abdomen and upper airway. Information on the Phase III clinical study with RUCONEST in acute attacks of HAE is available at clinicaltrials.gov by clicking here.
Rifamycin SV MMX®
Rifamycin SV MMX is an investigational product that is a broad spectrum, oral, non-systemic antibiotic being evaluated in a Phase III program for the treatment of travelers’ diarrhea, the most common illness affecting travelers caused by infectious agents such as bacteria, viruses or parasites. Information on the Phase III clinical study with rifamycin SV MMX in travelers’ diarrhea is available at clinicaltrials.gov by clicking here.
SAN-300 (anti-VLA-1 antibody)
SAN-300 is an investigational product that is a humanized anti-VLA-1 monoclonal antibody and an inhibitor of VLA-1, also known as α1β1 integrin. We believe that SAN-300 is a drug candidate that has potential application in multiple inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma and organ transplantation. We have completed a Phase I clinical program with SAN-300 and we plan to begin a Phase IIa clinical study evaluating SAN-300 for the treatment of patients with rheumatoid arthritis during the fourth quarter of 2013.